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Abstract
Matrix metalloproteinase-19 (MMP19) affects cell proliferation, adhesion, and migration in vitro but its physiological role in
vivo is poorly understood. To determine the function of MMP19, we generated mice deficient for MMP19 by disrupting the
catalytic domain of mmp19 gene. Although MMP19-deficient mice do not show overt developmental and morphological
abnormalities they display a distinct physiological phenotype. In a model of contact hypersensitivity (CHS) MMP19-deficient
mice showed impaired T cell-mediated immune reaction that was characterized by limited influx of inflammatory cells, low
proliferation of keratinocytes, and reduced number of activated CD8
+ T cells in draining lymph nodes. In the inflamed tissue,
the low number of CD8
+ T cells in MMP19-deficient mice correlated with low amounts of proinflammatory cytokines,
especially lymphotactin and interferon-inducible T cell a chemoattractant (I-TAC). Further analyses showed that T cell
populations in the blood of immature, unsensitized mice were diminished and that this alteration originated from an altered
maturation of thymocytes. In the thymus, thymocytes exhibited low proliferation rates and the number of CD4
+CD8
+
double-positive cells was remarkably augmented. Based on the phenotype of MMP19-deficient mice we propose that
MMP19 is an important factor in cutaneous immune responses and influences the development of T cells.
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Introduction
Matrix metalloproteinases (MMPs) are zinc-dependent endo-
peptidases that are responsible for processing extracellular matrix
(ECM) proteins and a number of cell surface receptors, their
ligands, and adhesion molecules. These proteolytical activities
have direct impact on cell behavior, proliferation, and survival
(reviewed in [1–3]).
MMP19 was originally isolated from the inflamed synovium of a
rheumatoid arthritis patient [4], from mammary gland, and liver
[5,6]. Human and murine orthologues of MMP19 (human:
U37791, murine: AF153199) retain the common domain
organization of soluble members of the MMP family, however,
they also contain several distinctive features including the insertion
of a unique cysteine in the catalytic domain, an altered latency
motif, a unique oligoglutamate insertion in the hinge region, and a
C-terminal tail [4–9]. At the mRNA level, MMP19 is expressed in
many tissues [5,6]. However, the expression at the protein level
appears to be more restricted. Vascular smooth muscle cells,
myoepithelial cells, and basal keratinocytes express MMP19
constitutively whereas endothelial cells, epithelial cells of the
mammary glands, and monocytes show differential regulation of
this enzyme [10–15]. In addition to its characteristic expression
pattern in the vicinity of basement membranes, MMP19 is able to
cleave extracellular matrix (ECM) components such as type IV
collagen, c2 chain of laminin 5, nidogen-1, the large tenascin-C
isoform, fibronectin, cartilage oligomeric matrix protein (COMP),
and aggrecan [9,16–18]. Moreover, MMP19 effectively cleaves
insulin-like growth factor binding protein-3 (IGFBP-3) as we
showed previously [14]. MMP19 was also reported to be expressed
in macrophages [15,19] and upregulated under inflammatory
conditions such as arthritis and multiple sclerosis [20–22].
Recently, it became obvious that beside their role in matrix
processing MMPs are important in the development and outcome
of inflammatory responses by activating and releasing cytokines,
establishing a chemokine gradient, controlling cell migration and
survival, and contributing to epidermal barrier function [23].
To reveal specific functions of an MMP in a cutaneous immune
response as well as in the epidermis, immune reactions of delayed-
type hypersensitivity (DTH) are especially useful due to their well
characterized course. Contact hypersensitivity (CHS) represents a
subtype of DTH reactions in the skin that is used as model for
allergic contact dermatitis mediated by T lymphocytes [24,25].
Upon cutaneous contact with haptens, small molecules, which act
as antigen, T lymphocytes are activated by Langerhans cells, i.e.
epidermal dendritic cells (DCs). Antigen-bearing DCs are targeted
to regional lymph nodes (LN) and present the antigen to activate
and clonally expand specific T cell precursors. During the efferent
phase, after secondary exposure to the hapten both CD4
+ and
CD8
+ T cells are recruited into the skin. CD8
+ T cells appear to be
PLoS ONE | www.plosone.org 1 June 2008 | Volume 3 | Issue 6 | e2343key effectors of CHS, since depletion of CD8
+ T cells reduce CHS
while MHC class II-deficiency leads to enhanced response [26–
31]. CD4
+ T cells have a prominent role in the resolution and
downregulation of CHS [24,32,33].
Hapten application induces secretion of cytokines by various cell
types in the skin. Involvement of interleukin-1 (IL-1), tumor
necrosis factor a (TNF-a), and monocyte chemoattractant protein-
1 (MCP-1) during early stage of sensitization has been reported
[34–38]. For T cell activation and generation of memory T cells
promoting cytokines like IL-16, MCP-1, MIF, and IL-2 are of
crucial importance [39–43]. During the elicitation phase of CHS
at the site of hapten challenge, cytokines such as TNF-a,
interferon-c (IFN-c), growth-related oncogene-a (Gro-a), MCP-
1, and RANTES (regulated and normal T cell expressed and
secreted) recruit neutrophils and eosinophils while lymphotactin
and I-TAC are responsible for the activation and recruitment of T
cells [38,44–53].
To exercise a control function in the periphery, effector T cells
that are responsible for immune reactions such as CHS have to
undergo a proper and accurate development and distribution. In
the thymus T lymphocytes develop from early thymocyte
progenitors to differentiated, functional T cells that emigrate to
the periphery. During their maturation CD4 and CD8 single-
positive (SP) mature T lymphocytes develop through differentia-
tion stages involving CD4
2CD8
2 double-negative (DN) and
CD4
+CD8
+ double-positive (DP) thymocytes. DP thymocytes that
fail the selection process or are negatively selected die at this stage.
Positive selection leads to transition into SP thymocytes and
emigration of mature T cells into periphery. Throughout the
maturation process thymocytes have to migrate through cortical
and medullary regions along ECM components like laminins,
fibronectin, and collagen IV [54], which in part is mediated by the
action of MMPs [55].
To analyze the function of MMP19 in vivo mice deficient in
mmp19 gene expression were generated via targeted mutagenesis.
Since MMP19 is abundantly expressed in the epidermis and is
upregulated under inflammatory conditions we focused our
investigations onto immune reactions in the skin. To study the
effect of MMP19 in T cell-mediated immune responses we used
fluorescein isothiocyanate (FITC) as a hapten in the model of CHS
and analyzed activation of DCs and CD8
+ T cells. We show here
that MMP19-deficient mice exhibited a limited inflammatory
reaction in response to the hapten marked by lowered cytokine
expression, decreased influx of inflammatory cells, low prolifera-
tion of keratinocytes, and diminished activation and distribution of
CD8
+ T cells. Since differences or depletion of T cell subsets could
alter the CHS response [26,27,29,56] we further analyzed T cell
populations in the blood and thymus under normal unsensitized
conditions. Relative numbers of single-positive CD4
+ and CD8
+ T
cells were reduced in the blood and thymus whereas the number of
CD4
+CD8
+ double-positive T cells in the thymus was remarkably
augmented. Thus, MMP19 is an important factor, which is
necessary for proper immune response in the skin and for
development and distribution of T cell populations.
Results
Generation of MMP19-deficient mice
In order to assess the physiological function of MMP19, we
constructed a targeting vector that replaced the catalytic domain
with a neoR cassette orientated in the opposite direction to the
endogenous mmp19 gene (Fig. 1A). To determine mice carrying the
targeting construct Southern blot analysis and PCR of DNA from
newborn mice were carried out (Fig. 1B and C). The absence of
MMP19 protein in MMP19-deficient (MMP19
2/2) mice was
demonstrated by immunoblotting of cell lysates prepared from
MMP19
2/2, heterozygous (MMP19
+/2), and wild-type primary
keratinocytes (Fig. 1D). The absence of MMP19 at the protein
level in MMP19
2/2 mice was also shown by immunohistochem-
ical analysis of murine skin with antibodies directed against the
hinge region of mouse MMP19 (Fig. 1E).
Mice homozygous for the targeted gene were observed for more
than one year. They developed without obvious alteration in gross
morphology, weight, size, and fecundity compared to wild-type
mice. Breeding mice heterozygous for the targeted gene produced
the expected Mendelian ratio of knockout animals of 25%. Thus,
MMP19 does not seem to be essential for blastocyst implantation
or embryonic development. No apparent changes in the histology
of brain, bones, heart, kidney, liver, lung, reproductive organs,
pancreas, skin, and spleen of MMP19-deficient mice were seen at
1, 3, 6, and 12 months (data not shown).
MMP19
2/2 mice exhibit impaired CHS
To investigate the role of MMP19 in immune responses
MMP19
2/2 mice and wild-type control mice were studied in a
model of CHS. In order to follow up the activation and migration
of DCs in the first stage of CHS, FITC was used as a fluorogenic
hapten that facilitates the detection of activated DCs, i.e. FITC-
positive DCs, in lymph nodes by flow cytometry. No significant
differences in the number or activation (CD80, CD86, MHC class
II expression) of DCs could be detected between MMP19
2/2 and
MMP19
+/+ mice (not shown). After cutaneous sensitization and
challenge of the mice by painting FITC on one ear, wild-type mice
developed a local inflammatory response that was measured as an
increase of ear thickness with a peak around 24 h after challenge
(Fig. 2A). This swelling declined slowly during the period of three
days. In contrast, ear swelling was abrogated in MMP19-deficient
mice (Fig. 2A). Histology of ears 24 h post FITC challenge
revealed strong infiltration of inflammatory cells in MMP19
+/+
mice that was not observed in MMP19
2/2 mice (Fig. 2B). The
inflammatory reaction in wild-type mice was accompanied by a
strongly increased proliferation of keratinocytes resulting in a
thickened epidermis. The activation and thickening of the
epidermis were absent in MMP19
2/2 mice (Fig. 2B and C).
Evaluation of keratinocytes positive for the proliferation marker
Ki-67 showed that 60% of total and basal keratinocytes were
proliferating in MMP19
+/+ mice while in MMP19-deficient mice
only 20% of keratinocytes proliferated (Fig. 2C). Since MMP19 is
known to affect keratinocyte proliferation by processing IGFBP-3
[14], we isolated primary mouse keratinocytes from MMP19
2/2
and wild-type mice and compared their capacity to process
IGFBP-3 using western blot analysis. While keratinocytes from
MMP19
+/2 mice exhibited usual degradation of IGFBP-3,
keratinocytes deficient for MMP19 showed predominantly the
unprocessed form of IGFBP-3 (Fig. 2D).
Since FITC-stimulated CHS response is mainly mediated by
CD8
+ T cells [57,58], we determined the presence of CD8
+ cells in
ears of wild-type and MMP19
2/2 mice 24 h after FITC challenge
as well as in unsensitized mice. In contrast to wild-type mice with
abundantly dispersed CD8
+ T cells in the challenged ear
MMP19
2/2 mice showed low numbers of T cells that were
comparable to the unsensitized situation (Fig. 2E). To test whether
the distribution of CD8
+ T cells in MMP19
2/2 mice differs from
that of wild-type mice also under non-T cell-dependent inflam-
mation, mouse ears were treated by a single painting of croton oil
as unspecific, inflammatory stimulus. After 24 h, abundance of
CD8
+ T cells in MMP19-deficient mice was very low compared to
wild-type mice (Fig. 2E). These findings indicate that MMP19
2/2
MMP19 in Immune Reactions
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proliferation, and CD8
+ T cell circulation.
MMP19
2/2 mice exhibit reduced production of
inflammatory cytokines at the site of inflammation
Within inflamed tissues chemokines serve as main attractants for
monocytes and T lymphocytes. Using a cytokine antibody array
we compared ears of wild-type and MMP19
2/2 mice for cytokine
expression 24 h after FITC challenge. Generally, MMP19
2/2
mice showed a reduction of all detectable cytokines when
compared to MMP19
+/+ mice. Fig. 2F shows a representative
evaluation of these analyses with highest reduction in lymphotactin
(5.1-fold) and IL-12 expression (4.3-fold). Other cytokines such as
CD30L, eotaxin, fractalkine, LIX (LPS-induced chemokine),
MCP-1, and MCSF (macrophage colony stimulating factor) were
moderately reduced. IFN-c, IL-4, and IL-5 were not detectable in
these assays. Interestingly, lymphotactin and I-TAC, both
responsible for activation and recruitment of T cells, showed
continuously lower expression in MMP19
2/2 mice (Fig. 2G).
These results correspond with the previous analyses showing low
inflammatory response in MMP19
2/2 mice and point to a biased
distribution of T cells at the inflammatory site.
MMP19-deficiency results in reduced activation of T cells
Development of CHS depends on the stimulation and activation
of antigen-specific T cells. We analyzed CD8
+ T cells in
Figure 1. Generation of MMP19
2/2 mice. (A) Schematic representation of the murine mmp19 gene and its exon/intron-organization as
previously described by Mueller et al. [7]; pPNT targeting vector construct, and the resulting deleted active site locus of the mouse mmp19 gene are
depicted. The targeting construct based on the pPNT vector [70], was generated by replacement of 1088 bp region of mmp19 gene spanning the end
of exon 3 and the whole exon 4 encoding the catalytic domain by the neomycin resistance cassette. Homologous recombination led to introduction
of the PGK-Neo cassette and allowed selection of homologous recombinants. The 39-probe used for detection of replacement events is indicated by
thick bars. Also shown are restriction sites used for southern hybridization screening as well as primer binding sites used for diagnostic PCR.
Screening for replacement mutants employed restriction digestion of genomic DNA with StuI and EcoRV and southern hybridization with the
described 39-probe. (B) For screening of MMP19-deficient mice Southern blot analyses were performed: mouse DNA digested with StuI and EcoRV
was probed with the diagnostic 39-probe. Probing led to identification of either a 7.3 kb band (wild-type allele, +/+) or a 5 kb band for the targeted
allele (2/2). In heterozygous mice (+/2) both alleles are present. (C) Genotyping of targeted alleles using PCR. Wild-type alleles are detected by an
800 bp band, while PCR for the MMP19-deficient allele results in a 600 bp product. (D) Primary keratinocytes isolated from wild-type, heterozygous,
and homozygous MMP19-deficient mice were analyzed for MMP19 expression by western blotting using anti-MMP19 antibodies purified against a
peptide derived from the hinge region of murine MMP19, that is deteced in size of 59 kD. (E) Immunohistochemical analysis of murine skin with anti-
MMP19 antibodies described above. Scale bars: 50 mm.
doi:10.1371/journal.pone.0002343.g001
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as well as in FITC-challenged mice with an active CHS response
in the efferent phase, 48 and 72 h after treatment with the hapten.
Unsensitized MMP19
2/2 mice exhibited slightly reduced
amounts of CD62L
+ and CD25
+/CD95
+ cells in inguinal LN
(Fig. 3A). Cells positive for CD69, CD44, and CD122 showed no
differences under unsensitized conditions. 24 h after FITC-
sensitization, i.e. abdominal hapten application, wild-type mice
showed activation of T cells with increased amount of CD69
+ and
reduction of CD62L
+ cells. In contrast, CD8
+ T cells in inguinal
Figure 2. MMP19
2/2 mice show impaired ear swelling and inflammatory reaction in CHS. (A) Five days after abdominal sensitization with the
hapten(FITC), mouseearswerechallenged withFITC andear thickness was measured after 24, 48, and72 h.Mean values aregivenin mm as difference to
timepoint0 h.(B)Hematoxylin-eosinstainingofearsections24 hafterchallengeshowsreducedinfluxofneutrophilsandeosinophilsinMMP19
2/2mice.
(C) Staining with anti-Ki-67 antibody revealed that proliferation of keratinocytes in MMP19-deficient mice was strongly reduced in basal and suprabasal
layers. Ki-67-positive cells were counted and calculated as percentage of basal and total keratinocytes. Six images (magnification 400x) per mice were
analyzed. (D) Decreased processingofIGFBP-3 inMMP19-deficientmice.Primary keratinocytes fromMMP19
+/2 andMMP19
2/2 miceweregrownfor72 h
and conditioned media were analyzed for IGFBP-3 proteolysis by western blotting. The arrowhead indicates the position of intact IGFBP-3, whereas the
arrow points to 30 kD IGFBP-3 proteolytic fragment. (E) Anti-CD8 staining (red) of ear sections. MMP19
2/2 mice show low numbers of CD8
+ T cells in CHS
(upper panel) as well as in a T cell-independent model of inflammation, i.e. irritant dermatitis, induced by croton oil (middle panel). Ears of unsensitized
mice (lower panel) exhibit low numbers of CD8
+ cells; no difference was observed between MMP19
+/+ and MMP19
2/2 mice. CHS and irritant dermatitis
werecarried out infour independent experimentseach with4 wild-typeand 4 MMP19
2/2 mice.(F) 24 h after FITCchallenge earlysates wereanalyzed for
cytokine expression that was generally reduced in MMP19-deficient mice compared to wild-type animals. (G) Reduced levels of lymphotactin and I-TAC
from three independent experiments are shown. Bars in F and G represent values of MMP19
2/2 mice given as fold decrease to wild-type mice. Significant
values with *p,0.05 and **p,0.01; student’s t-test. Scale bars: B, 50 mm; C, 20 mm; D, 50 mm.
doi:10.1371/journal.pone.0002343.g002
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reduced activation (Fig. 3B). Numbers of activated CD8
+ T cells
positive for CD62L/CD69, CD44/CD69, and CD44/CD122
were significantly reduced compared to wild-type mice whereas
the number of naive CD62L
+ cells remained similar to the
unsensitized situation indicating lack of activation (Fig. 3A). Five
days after FITC sensitization, i.e. after memory T cells were
generated, mice ears were challenged with FITC to induce CHS
reaction. 24 h after challenge in correlation to the maximal
inflammatory ear swelling response, the population of activated
CD8
+ T cells in the draining lymph nodes (DLN) of MMP19
2/2
mice was strikingly diminished. Significant differences between
MMP19
2/2 and wild-type mice were observed for CD8
+ T cells
expressing CD44
high, CD44/CD69, and CD25 (Fig. 3C). Al-
though 72 h after FITC challenge MMP19
2/2 mice did not show
any inflammatory signs in the ears, CD8
+ T cells in DLN from
MMP19
2/2 mice showed still some differences: the number of
CD62L
+ cells was increased and CD25
+ cells diminished (Fig. 3D).
We also analyzed DCs in DLN and observed no significant
differences in CD80, CD86, CD40, and MHC class II positive
cells between MMP19
2/2 and wild-type mice (not shown). These
results point out a significant role of MMP19 in T cell activation as
well as in T cell distribution in peripheral tissues.
Immature MMP19
2/2 mice show low numbers of CD4
+
and CD8
+ T cells in peripheral blood
Since differences in T cell populations between MMP19
2/2
and wild-type mice were observed in the periphery and in lymph
nodes, we were interested if the T cell population is also biased in
the circulation. Blood of immature and mature unsensitized
MMP19
2/2 and wild-type mice were analyzed for the basic cell
types. Analyzing T cell subpopulations we observed reduced
numbers of CD8
+ and CD4
+ T cells in the blood of immature (3
weeks old) MMP19
2/2 mice (Fig. 4A and B) whereas B
lymphocytes (B220), monocytes (CD11b), and granulocytes (Ly-
6) showed numbers comparable to MMP19
+/+ mice. Analysis of 3
months old mice, i.e. adult mice, did not reveal any difference in T
cell populations between MMP19
2/2 and wild-type mice
although the latter showed a tendency to increased amounts of
Figure 3. MMP19
2/2 mice exhibit reduced T cell activation in CHS. Using flow cytometry cells of inguinal (A and B) or draining lymph nodes
(C and D) from wild-type (+/+) and MMP19-deficient (2/2) mice were analyzed for the indicated activation markers, all gated on CD8
+ T cells. (A)
Unsensitized MMP19
2/2 mice show slight decrease of T cells positive for CD62L and CD95/CD25. (B) MMP19
2/2 mice analyzed 24 h after abdominal
FITC painting (sensitization) exhibit higher numbers of naive T cells (CD62L
+) and decreased numbers of activated T cells compared to MMP19
+/+
mice. (C) In CHS reaction 48 h after FITC challenge on ears, draining lymph nodes of MMP19
2/2 mice show significantly reduced numbers of cells
positive for activation and memory markers. (D) Reduced numbers of CD25
+ and high numbers of CD62L
+ cells are still present in MMP19
2/2 mice
after 72 h while other activation markers were comparable to those of MMP19
+/+ mice. In A and B two scales are used to match relevant data from an
identical experiment. Significant values (p,0.05) are marked by asterisk. Each analysis was carried out four times with MMP19
+/+ (n=4) and MMP19
2/2
mice (n=4) per experiment.
doi:10.1371/journal.pone.0002343.g003
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+ cells (Fig. 4C). Hence, the MMP19-deficiency influenced T
cell proportions in the blood of immature mice.
Thymocytes of immature MMP19
2/2 mice exhibit
decreased proliferation and reduced maturation
Searching for the origin of biased T cell population in blood,
lymph nodes, and in peripheral tissues of MMP19
2/2 mice we
examined subset distribution of T cells in the thymus. Immature
MMP19
2/2 mice at the age of 3–4 weeks exhibit higher numbers
of CD4
+CD8
+ DP cells and reduced levels of CD4
+ and CD8
+ SP
cells compared to wild-type mice (Fig. 5A and B). In contrast,
analysis of adult animals showed similar amounts of DP and SP
cells in the thymus (Fig. 5C). This observation is in concordance
with low amounts of SP T cells in blood of immature MMP19
2/2
mice (Fig. 4). Furthermore, staining of thymocytes from 3-weeks
old animals for the proliferation marker Ki-67 revealed low
amounts of proliferating cells (Fig. 6A). These results were also
confirmed in vivo by using BrdU incorporation. The incorporation
Figure 4. T cell population in blood of immature MMP19
2/2
mice is distorted. (A) Blood samples of 3-weeks old MMP19
+/+ and
MMP19
2/2 mice were analyzed for monocytes, granulocytes (CD11b
and Ly-6), B cells (B220), and T cell populations by flow cytometry.
MMP19
2/2 mice exhibit significantly reduced numbers of CD4
+ and
CD8
+ T cells. (B) A typical dot plot analysis of CD4
+ and CD8
+
populations gated on CD3
+ cells in individual mice is shown. (C) No
differences in T cell subpopulations were measured in blood of adult
mice (12 weeks old). CD4
+ and CD8
+ T cells shown in A and C are also
positive for CD3. Analyses were carried out in five independent
experiments with MMP19
+/+ (n=4) and MMP19
2/2 mice (n=4).
Numbers of B and T lymphocytes were analyzed by gating the
lymphocyte region. Significances with *p,0.05; student’s t-test.
doi:10.1371/journal.pone.0002343.g004
Figure 5. Development of single positive lymphocytes in the
thymus of MMP19
2/2 mice is impeded. Flow cytometry analysis of
thymocytes from immature (3-weeks old, A and B) and adult (8–12
weeks, C) MMP19
+/+ and MMP19
2/2 mice. (A) Young MMP19
2/2 mice
have high numbers of CD4
+/CD8
+ T cells and lower numbers of CD8
single-positive thymocytes compared to MMP19
+/+ mice. (B) A typical
dot plot analysis of CD4
+ and CD8
+ T cell populations gated on CD3
+
cells shows a decrease of single-positive and accumulation of double-
positive T cells in thymi of MMP19
2/2 mice. (C) Adult MMP19
+/+ and
MMP19
2/2 mice show equal numbers of T cell subsets in the thymus.
Analyses were done in four independent experiments with MMP19
+/+
(n=4) and MMP19
2/2 mice (n=4). Significant values with *p,0.05 and
**p,0.01; student’s t-test.
doi:10.1371/journal.pone.0002343.g005
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2/2 mice was significantly
reduced in comparison to MMP19
+/+ mice (Fig. 6B and C). This
altered proliferation in MMP19
2/2 mice was not restricted to
particular T cell subsets, since CD3
+, CD8
+, and CD4
+ cells
showed a similar degree of BrdU incorporation (Fig. 6C). To get a
clue whether these changes could be directly mediated by the lack
of MMP19 we studied the morphology of thymi from MMP19-
deficient and wild-type mice and the expression of MMP19 using
quantitative RT-PCR. Wild-type mice exhibited a low but defined
expression of MMP19 in the thymus (Fig. 6D). Thus, MMP19
might be important for defining the thymic microenvironment or
for migration of thymocytes among various niches. Analyzing the
morphology of thymi from MMP19
+/+ and -deficient mice we
observed no differences in the cortical and medullar structure (not
shown). Formation of the thymic vasculature was not altered, as
the expression pattern of VE-cadherin, an endothelial marker, was
comparable between wild-type and MMP19
2/2 mice (not shown).
Thus, MMP19 might influence the transition of DP thymocytes to
SP mature T cells.
Discussion
The present studies show that MMP19 plays a pivotal role during
T cell-mediated cutaneous immune response and has an impact on
the development of T lymphocytes. MMP19-deficient mice
generated by disrupting its catalytic domain show no obvious
morphological and developmental abnormalities. This is consistent
with the work of Pendas et al. [59] who generated MMP19-deficient
mice by replacing the promoter region and exons 1 and 2. Pendas
and colleagues studied functions of MMP19 in metabolism,
carcinogenesis, and angiogenesis and showed that MMP19-deficient
mice are more susceptible for skin tumors and exhibit earlier tumor
angiogenesis [59,60].Wehave studied MMP19 intheskinimmunity
and our results, together with the work on skin tumorigenesis show
that MMP19 has indispensable functions in cutaneous homeostasis.
In the CHS model, the deficiency of MMP19 severely impaired
the overall inflammatory response to the hapten suggesting a
requirement of this MMP in cutaneous inflammation. A similar
reduction of the inflammatory reaction in CHS was described also
in stromelysin-1 (MMP3)-deficient mice while the lack of MMP9
resulted in the prolongation of the response. Interestingly,
deficiency of MMP3 and MMP9 weakened also the immune
reaction in the lung during acute injury although only MMP3
affected the influx of neutrophils [61]. Neutrophils are also
controlled by MMP12 as MMP12-deficient mice exhibit a
markedly reduced influx of neutrophils into the alveolar space
during acute lung injury [62]. In general, the involvement of
MMPs in immune reactions is only purely characterized,
nevertheless studies with mice deficient in MMP9 and MMP7
showed that MMPs are essential for development of inflammation
and its resolution (reviewed in Hu et al. [63]).
The lack of MMP19 not only considerably reduced the skin
inflammation characterized by low influx of inflammatory cells as
reported for MMP3-deficiency, but also reduced proliferation of
keratinocytes and strikingly diminished activation of CD8
+ T cells
which are responsible for this type of reaction. This diminished
Figure 6. Thymocytes of MMP19
2/2 mice exhibit strongly reduced proliferation. (A) Immature MMP19
2/2 mice exhibit low numbers of Ki-
67
+ medullar cells in the thymus. Scale bars: 50 mm. (B and C). To quantify proliferating thymocytes mice were injected i.p. with BrdU. After 14 h,
CD3
+, CD4
+, and CD8
+ thymocytes were analyzed for BrdU incorporation using flow cytometry. Grey, isotype control; light red, MMP19
2/2 (n=4); red,
MMP19
+/+ (n=4). (C) Quantification of BrdU positive thymocytes. CD3
+, CD4
+, and CD8
+ thymocytes from MMP19
2/2 mice exhibit markedly
diminished proliferation. Black bars: MMP19
+/+, white bars: MMP19
2/2. (D) Quantitative RT-PCR analysis of MMP19 in the thymus shows expression in
WT mice and confirmed the absence in MMP19
2/2 mice. The expression of MMP19 in the thymus is lower compared to that in the liver. CT, cycle of
threshold. Significances with **p,0,01 (student’s t-test).
doi:10.1371/journal.pone.0002343.g006
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and to present the hapten to T cells since the numbers and the
activation state of DCs in MMP19
2/2 and wild-type mice were
comparable (not shown) in inguinal draining LNs.
With regard to the impaired inflammation it is possible that the
amount of proinflammatory factors produced from the epidermis
are not sufficient for the attraction and migration of T cells. This is
also supported by markedly reduced concentrations of a number
of cytokines including lymphotactin and I-TAC. Lymphotactin is a
powerful attractant for T cells and is expressed by activated CD8
+
T cells and by epidermal dendritic T cells affecting migration of
CD8
+ T cells. I-TAC, interferon-inducible T cell a chemoattrac-
tant (also known as CXCL11 or IP-9) that is also produced by
keratinocytes binds to the chemokine receptors CXCR7 and
CXCR3 and exhibits potent chemoattractant activity for inter-
leukin-2-activated T cells [47,48,52,64]. Since CD8
+ T cells were
less abundant at the inflammatory sites of MMP19
2/2 mice than
in control mice we suggest that the MMP19-dependent dysreg-
ulation of chemokines, such as lymphotactin and I-TAC, is
responsible for the skewed distribution and circulation of T cells in
the periphery and in LN. Thus, we suppose that proinflammatory
factors produced by the inflamed tissue itself could contribute to T
cell distribution and the skewed inflammatory reaction in
MMP19
2/2 mice.
The diminished production of inflammatory mediators corre-
lated not only with reduced proliferation of keratinocytes in
MMP19
2/2 mice but also with markedly reduced processing of
IGFBP-3 in keratinocytes. In our previous work we could show in
vitro that MMP19-dependent proteolysis of IGFBP-3 leads to
activation of IGF-signaling pathway and, thus, to increase of
proliferation, production of proinflammatory factors, and cell
migration [14]. Alterations of the immune response in MMP19
2/2
mice not only point towards the role of MMP19 in controlling
attraction and circulation of inflammatory cells but reveal also an
option that T cell populations in MMP19
2/2 mice might be
generally biased. Indeed, the analysis of blood cells disclosed that
CD4
+ and CD8
+ T cell populations are significantly diminished in
immature mice. Reduced numbers of cells positive for CD3, CD4,
and CD8 in the blood appear to be a direct consequence of the
situation in the thymus. Thymi of immature MMP19
2/2 mice
exhibited increased numbers of CD4
+CD8
+ DP thymocytes while
the number of CD8
+ T cells was diminished. The numbers of CD4
+
T cells were not significantly altered. Thus, thymocytes in immature
MMP19 mice exhibit a delayed transition of DP cells into the SP
state that is compensated with increased age. This distorted T cell
development and biased T cell subpopulations in the blood are most
likely not responsible for abrogation of the cutaneous inflammatory
reaction since adult mice that were used for experiments did not
exhibit these differences. Thus, MMP19 affects the local inflamma-
tion independently from developmental alterations of T cells.
MMP19 was previously reported to be abundant in human
thymus [6] which is in line with its expression in mouse thymi.
Although the underlying mechanism of MMP19 function in the
thymus is currently not known, former studies with metalloprotei-
nases (MP) inhibitors indicated possible functions of MP. They
significantly reduced the numbers of CD4
+CD8
+ DP and mature SP
T cells, inhibited thymocyte proliferation, and led to incomplete
upregulation of CD25 (IL-2 receptor) [65]. MMP19
2/2 mice
showed both reduced proliferation of thymocytes and diminished
numbers of CD25
+CD8
+ T cells during sensitization and effector
phase of CHS. Although several MMPs are expressed in the thymus
their specific role is unknown [55,66,67]. It was, however, suggested
that MT1-MMP that is upregulated by thymocytes upon contact to
laminin 5 contributes to thymocyte migration via releasing CD44
[55]. MMP19 might be also involved in adhesion, detachment, and
migration of thymocytes since it processes several ECM proteins
including type IV collagen, nidogen-1, and laminin 5 c2t h a tw e r e
reported to be relevant for the migration and development of
thymocytes [16,17,68]. However MMP19 is not the only protease
that is able to process these substrates and, thus, cooperation of
different MMPs and other proteases may lead to efficient processing
of ECM proteins in vivo. The phenotypic changes that were found in
MMP19-deficient mice could be rather a result of combined
processing of multiple substrates than outcome of one major
substrate. Moreover, we cannot exclude that beside IGFBP-3
processing, which is able to affect a number of cellular processes,
MMP19 could also process and activate chemokines and proin-
flammatory cytokines as reported for other MMPs (reviewed in Van
Lint P. and Libert C. [69])
Altogether, analysis of MMP19-deficient mice revealed that
MMP19 plays an important role in the development of the
cutaneous immune response, especially in CHS, and is involved in
development of T lymphocytes, their distribution, and activation.
Materials and Methods
Targeted disruption of the mmp19 gene
The targeting vector was designed to delete 1088 bp from the
region spanning the end of exon 3 and the complete exon 4
containing the active site of MMP19. For construction of the 59-arm
of the targeting construct, a 2.8 kb fragment spanning a region
including exon 2 and most of exon 3 was amplified from genomic
DNA using primers m1U-2/EcoRI (GACTTCAGGCTGGAAGA-
TATC) und m1D-5/EcoRI (AGATTTCTGGTTGAAGGG). The
39-armhomologyregionof2.8kbrangingfromexon5toexon8was
created using primers m1U-25b/XhoI (TCATGGCTCCTGTC-
TATGCTG) and m1D-31/NotI (GAACACCTTTTGATTAA-
CAGGC). The targeting construct pPNT/mmp19del was intro-
duced into E14 embryonic stem cells [70]. For screening, DNA from
G418/Gancyclovir-resistant colonies was digested with StuIa n d
EcoRVand assessed by Southern blotting using a nonoverlapping 39-
probe generated by PCR with primers derived from exon 8 (m1-
U30, CGCTACCCTAAACCAATCAAG) and exon 9 (m1D-45,
CAGGAATGTGGTATCCAGAAG). The targeting event was
confirmed by Southern blot analysis using the strategy described
above, i.e. probing with the 39-probe led to identification of either a
7.3 kb band for the wild type or a 5 kb band for the targeted allele.
Two clones, F6 and G5, were microinjected into blastocysts and
chimeras were generated by standard techniques [71]. Upon germ
line transmission, animals carrying the mutant mmp19 allele were
crossed with C57BL/6 mice and two mouse lines (F6 and G5) were
established. Studies performed were done with mice backcrossed to
C57BL/6 background at least to the F12 generation. Housing of
mice and in vivo experiments were performed after approval by the
Animal Care Committee of the University of Kiel in compliance
with national and institutional guidelines.
PCR analysis
Mice were genotyped using PCR. WT allele: forward primer in
exon 4 (m1-U10, CCGCATCTTCAATGTGCCC) and a gene-
specific reverse primer from exon 5 (mD1-21, GATGCG-
CAGGTTCACTCC) amplified a 800 bp fragment from the wild-
type allele.Targetedallele:forward primerderived from exon 3(m1-
U3, AGATGGATGACGCCACAAG) and a reverse primer based
on the PGK-Neo cassette (neofwd, CTTCTATCGCCTTCTT-
GACG) amplified a 600 bp fragment. Amplification of genomic
DNA extracted from tail biopsies was performed using Taq DNA
polymerase (Fermentas AB, Vilnius, Lithuania) and a program of
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72uC (1 min). RNA was isolated with TRIZOL reagent (Invitrogen,
Carlsbad, CA). Quantitative PCR was performed using the ABI
7700PrismSequence Detection Systemand TaqManprimerprobes
specific for murine MMP19 and GAPDH (Applied Biosystems,
FosterCity, CA) as described [72]. Calculation of CT-values (cycle of
threshold) were done as described [72].
CHS model to FITC and irritant dermatitis to croton oil
CHS was carried out as described before [73,74]. Briefly, on
day 0 shaved mouse abdomens were painted with FITC (Sigma,
Steinheim, Germany). After 5 days mice were challenged with
FITC on both sides of one ear. Ear thickness was measured before
challenge (0 h) and at 24, 48, and 72 h using a micrometer
(Mitutoyo, Elk Grove Village, USA). DCs and T cells from
draining lymph nodes were isolated 48 and 72 h after challenge
and analyzed using flow cytometry. DCs were examined with
antibodies against CD11c (BD Biosciences, San Jose, CA), CD80,
CD86, and MHCII molecules (Caltag Laboratories, Burlingame).
T cells were stained with antibodies against CD8, CD62L, CD69,
CD44, CD122, and CD25 (BD Biosciences). DCs and T cells in
inguinal lymph nodes were analyzed 24 h after sensitization. The
model of irritant dermatitis was performed by application of
croton oil (0.8% in acetone) onto mice ears. Ears were analyzed by
immunohistochemistry 24 h after painting.
Immunohistochemistry
Tissue sections were stained either with eosin and hematoxylin
(Gill III, Thermo Shandon, Pittsburgh, PA) or with antibodies.
Monoclonal anti-Ki-67 antibodies (clone Tec3, diluted 1:50;
Glostrup, Dako Cytomation) and polyclonal rabbit antibodies raised
against a peptide derived from the hinge region of murine MMP19
was used. Bound antibodies were detected using the Vectastain ABC
Elite kit and AEC as substrate (both Vector Laboratories,
Burlingame, CA). For immunofluorescent detection tissues were
embedded in tissue freezing medium (Leica Instruments, Nussloch,
Germany) and monoclonal anti-CD8 (Chemicon, Temecula, CA)
and anti-Ki-67 antibodies were used. Antibodies were detected with
Cy3-conjugated goat anti-rat IgG antibodies (Dianova, Hamburg,
Germany) and visualized by a BX-50 fluorescence microscope
(Olympus, Tokyo, Japan). Images were processed with the Analysis
Soft Imaging system (Soft Imaging System, Lakewood, CA).
Isolation of primary keratinocytes and western blot
analysis
Primary keratinocytes were isolated from newborn (day 1 to 2)
mouseskinbytrypsinizationusingamodifiedprocedureasdescribed
previously [75] and grown in plastic vessels coated with type I
collagen (10 mg/cm
2) in keratinocyte medium (K-SFM) supple-
mented with EGF, BPE und 0,05 mM CaCl2 (Invitrogen, Carlsbad,
CA, USA) at 37uCu n d e r5 %C O 2. At confluency cell lysates were
prepared as described [13,14]. Protein was resolved on 10% SDS-
polyacrylamide gels, transferred to PVDF membranes (Macherei-
Nagel, Du ¨ren, Germany), and analyzed for MMP19 using
polyclonal antibodies purified against a peptide derived from the
hinge region of murine MMP19. IGFBP-3 processing was examined
with polyclonal antibodies detecting full-length form and fragments
of IGFBP-3 (Santa Cruz Biotechnologies, CA). Conditioned media
of keratinocytes were 10-fold concentrated.
Detection of cytokine expression
A mouse inflammation antibody array (Ray Biotech, Norcross,
GA) was used according to the manufacturer’s instructions. 24 h
after CHS challenge inflamed ears were cut off and lyzed. A
500 mg aliquot of the tissue lysate was used for each array. Signal
intensity was evaluated via AIDA Image Analyzer Software
(Raytest, Straubenhardt, Germany).
Isolation and FACS analysis of blood and thymus cells
Mice were anaesthetized and blood was obtained via intracar-
dial punctation. After adding EDTA and washing cells with PBS
erythrocytes were lyzed for 15 min at room temperature in lysis
buffer (150 mM NH4Cl, 15 mM Na2CO3, 1 mM EDTA,
pH 7.5). Thymi were excised immediately after the punctation.
Cells were stained with anti-CD3, -CD4, and -CD8 antibodies
(mouse T lymphocyte antibody cocktail, BD Biosciences). Blood
cells were further stained against CD11b (Caltag), CD45R (B220),
and Ly-6C/G (both BD Biosciences). Flow cytometry was carried
out using a FACScanto (BD Biosciences).
Thymocyte proliferation
To analyze proliferation by immunohistochemistry, sections of
thymi were stained with anti-Ki-67 antibodies as described above.
To quantify the proliferation mice were injected i.p. with 1 mg
BrdU in 1ml PBS. After 14 h thymocytes were stained with
antibodies against CD3, CD4, and CD8 (BD Biosciences). After
fixation and permeabilization cells were incubated with FITC-
conjugated anti-BrdU antibodies (Santa Cruz Biotechnologies,
CA) and analyzed by flow cytometry.
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